NEW YORK (
CHANGE IN RATINGS
(FOR) was upgraded to buy at TheStreet Ratings.
(NBN) was downgraded to hold at TheStreet Ratings.
(INTC - Get Report) earnings estimates were reduced at UBS. The lowered outlook reflects a sub-seasonal PC client trend, said UBS. Price target remains $22.50.
price target was increased to $105 by JPMorgan. Palbociclib (palbo, or PD-991), a breast cancer drug, is now included in the valuation, said JPMorgan.
(VRSN - Get Report)
price target was increased to $50 at Citigroup. The new price target reflects the likelihood of a significant debt raise, said Citigroup.
(Z - Get Report)
price target increased at Citi. The initial mid-term outlook provided at Z's fist analyst day led to a new price target of $70, said Citigroup.
estimates and price target cut at MKM. RHT earnings estimates through 2014 were reduced on management guidance, said MKM Partners. The new price target is $53.
price target was reduced to $29 at Benchmark. Lower fiscal 2Q guidance reflects uncertainty related to its ongoing business transformation, said Benchmark.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts